Sutro Biopharma, Inc. SEC filings STRO

Sutro Biopharma, Inc. has 624 filings in SEC EDGAR's recent list, going back to Nov 8, 2006. Its latest annual report, Form ARS, was filed on Apr 22, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 12, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Aug 12, 2026 (results of operations, regulation fd disclosure). The company's fiscal year ends on December 31.

Sutro Biopharma, Inc. SEC filings
Form Description Filed Period
DEFA14A Additional proxy material Apr 22, 2026 —
DEF 14A Proxy statement Apr 22, 2026 Jun 5, 2026
DEFA14A Additional proxy material Apr 25, 2025 —
DEF 14A Proxy statement Apr 25, 2025 Jun 6, 2025
PRE 14A Preliminary proxy statement Apr 14, 2025 Jun 6, 2025
DEFA14A Additional proxy material May 17, 2024 —
DEF 14A Proxy statement Apr 26, 2024 Jun 6, 2024
DEFA14A Additional proxy material Apr 26, 2024 —
DEFA14A Additional proxy material Apr 28, 2023 —
DEF 14A Proxy statement Apr 28, 2023 Jun 8, 2023
PRE 14A Preliminary proxy statement Apr 14, 2023 Jun 8, 2023
DEFA14A Additional proxy material Apr 25, 2022 —
DEF 14A Proxy statement Apr 25, 2022 Jun 6, 2022
DEF 14A Proxy statement Apr 29, 2021 Jun 3, 2021
DEF 14A Proxy statement Apr 24, 2020 Jun 5, 2020
DEFA14A Additional proxy material Apr 26, 2019 —
DEF 14A Proxy statement Apr 26, 2019 Jun 7, 2019

Showing 17 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.

Company profile

Industry
Biological Products, (No Diagnostic Substances) (SIC 2836)
Listed as
STRO (Nasdaq)
Fiscal year ends
December 31
Headquarters
South San Francisco, CA
SEC filer status
Non-accelerated filer, Smaller reporting company
SEC CIK
1382101
Former names
SUTRO BIOPHARMA INC (until Nov 8, 2018); Fundamental Applied Biology Inc (until Oct 24, 2007)

Other Biological Products, (No Diagnostic Substances) companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.